Enfusion, Inc. (ENFN)

NYSE: ENFN · IEX Real-Time Price · USD
11.76
-0.22 (-1.84%)
Jan 27, 2023, 4:00 PM EST - Market closed

Total Valuation

Enfusion has a market cap or net worth of $811.28 million. The enterprise value is $747.73 million.

Market Cap 811.28M
Enterprise Value 747.73M

Important Dates

The next earnings date is Thursday, March 23, 2023, after market close.

Estimated Earnings Date Mar 23, 2023
Ex-Dividend Date n/a

Share Statistics

Enfusion has 68.99 million shares outstanding. The number of shares has decreased by -24.68% in one year.

Shares Outstanding 68.99M
Shares Change (YoY) -24.68%
Shares Change (QoQ) +55.78%
Owned by Insiders (%) 4.65%
Owned by Institutions (%) 108.00%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE 67.11
PS Ratio 5.73
Forward PS 4.19
PB Ratio 13.27
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 5.28
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.01

Current Ratio 8.01
Quick Ratio 7.72
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a

Financial Efficiency

Return on equity (ROE) is -309.20% and return on invested capital (ROIC) is -447.60%.

Return on Equity (ROE) -309.20%
Return on Assets (ROA) -163.10%
Return on Capital (ROIC) -447.60%
Revenue Per Employee $158,840
Profits Per Employee -$199,683
Employee Count 892
Asset Turnover 1.30
Inventory Turnover n/a

Taxes

In the past 12 months, Enfusion has paid $531,000 in taxes.

Income Tax 531,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -2.89% in the last 52 weeks.

Beta (1Y) n/a
52-Week Price Change -2.89%
50-Day Moving Average 10.70
200-Day Moving Average 11.49
Average Volume (30 Days) 320,354

Short Selling Information

The latest short interest is 1.86 million, so 2.70% of the outstanding shares have been sold short.

Short Interest 1.86M
Short Previous Month 1.66M
Short % of Shares Out 2.70%
Short % of Float n/a
Short Ratio (days to cover) 5.70

Income Statement

In the last 12 months, Enfusion had revenue of $141.69 million and -$178.12 million in losses. Loss per share was -$3.05.

Revenue 141.69M
Gross Profit 97.72M
Operating Income -305.83M
Pretax Income -177.59M
Net Income -178.12M
EBITDA -171.30M
EBIT -177.27M
Loss Per Share -$3.05
Full Income Statement

Balance Sheet

Cash & Cash Equivalents 63.54M
Total Debt n/a
Net Cash 63.54M
Net Cash Per Share $0.92
Equity / Book Value 61.13M
Book Value Per Share 0.89
Working Capital 84.04M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $823,000 and capital expenditures -$7.83 million, giving a free cash flow of -$7.00 million.

Operating Cash Flow 823,000
Capital Expenditures -7.83M
Free Cash Flow -7.00M
FCF Per Share -$0.08
Full Cash Flow Statement

Margins

Gross margin is 68.97%, with operating and profit margins of -215.85% and -125.71%.

Gross Margin 68.97%
Operating Margin -215.85%
Pretax Margin -125.34%
Profit Margin -125.71%
EBITDA Margin -120.90%
EBIT Margin -125.11%
FCF Margin -4.94%

Dividends & Yields

Enfusion does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield -21.96%
FCF Yield -0.86%
Dividend Growth (YoY) n/a
Payout Ratio n/a
Buyback Yield 24.68%
Shareholder Yield 24.68%
Dividend Details

Analyst Forecast

The average price target for Enfusion is $13.06, which is 11.05% higher than the current price. The consensus rating is "Buy".

Price Target $13.06
Price Target Difference 11.05%
Analyst Consensus Buy
Analyst Count 12
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a